Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial

Effect of Memantine on QT/QTc Interval in a Healthy Korean Population

(2021) Jin‐Woo Park et al.   Clinical Pharmacology in Drug Development

Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances

(2021) Aaron M. Orkin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome

(2020) Eric D. Hamlett et al.   GLIA

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers

(2019) Martin Valis et al.   Frontiers in Pharmacology

Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome

(2019) Sarah E. Lee et al.   TRENDS IN MOLECULAR MEDICINE

National population‐based estimates for major birth defects, 2010–2014

(2019) Cara T. Mai et al.   Birth Defects Research

Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome

(2018) Jonah J. Scott-McKean et al.   NEURAL PLASTICITY

Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis

(2017) Taro Kishi et al.   JOURNAL OF ALZHEIMERS DISEASE

Predictors of Age of Diagnosis and Survival of Alzheimer’s Disease in Down Syndrome

(2017) Amanda Sinai et al.   JOURNAL OF ALZHEIMERS DISEASE

Fitting Linear Mixed-Effects Models Usinglme4

(2015) Douglas Bates et al.   Journal of Statistical Software

The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration

(2014) Alberto Costa   CNS & Neurological Disorders-Drug Targets

Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome

(2013) Van Dang et al.   BIOLOGICAL PSYCHIATRY

Prospects for Improving Brain Function in Individuals with Down Syndrome

(2013) Alberto C. S. Costa et al.   CNS DRUGS

Pharmacotherapy of Vestibular Disorders and Nystagmus

(2013) Olympia Kremmyda et al.   SEMINARS IN NEUROLOGY

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial

(2012) Marisa Hanney et al.   LANCET

Treatment of Alzheimer disease in Down syndrome

(2012) Alberto C. Costa   Nature Reviews Neurology

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial

(2012) R Boada et al.   Translational Psychiatry

Validity of the California Verbal Learning Test–II in Multiple Sclerosis

(2009) Shane Stegen et al.   CLINICAL NEUROPSYCHOLOGIST